Evidence map›Paper›PMID 41710877›Full record

ArticleFrontiers in immunology2026

Evaluation of 3D biomimetic microcarriers for enhancing therapeutic efficacy of human umbilical cord mesenchymal stem cells in psoriasis treatment.

XueMei Li, YanMei Chen, JiaWei Cai, YuQiong Huang, XiangLong Chen, MingYu Yu, Li Fu, Bao Chai, Cheng Zhang, ZhiYong Zhang and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

XueMei Li *Department of Dermatology, Huazhong University of Science and Technology Union Shenzhen Hospital, Shenzhen, China.
YanMei Chen *Translational Research Centre of Regenerative Medicine and 3D Printing, The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China.
JiaWei CaiTranslational Research Centre of Regenerative Medicine and 3D Printing, The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China.
YuQiong HuangDepartment of Dermatology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
XiangLong ChenTranslational Research Centre of Regenerative Medicine and 3D Printing, The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China.
MingYu YuDepartment of Dermatology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Li FuGuangdong Province Key Laboratory of Regional Immunity and Diseases, Department of Pharmacology and Shenzhen University International Cancer Center, Shenzhen University Medical School, Shenzhen, China.
Bao ChaiDepartment of Dermatology, Huazhong University of Science and Technology Union Shenzhen Hospital, Shenzhen, China.
Cheng ZhangTranslational Research Centre of Regenerative Medicine and 3D Printing, The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China.
ZhiYong ZhangTranslational Research Centre of Regenerative Medicine and 3D Printing, The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China.
HongXiang ChenDepartment of Dermatology, Huazhong University of Science and Technology Union Shenzhen Hospital, Shenzhen, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mesenchymal stem cells (MSCs) hold promise for regenerative medicine due to their unique biological properties, including self-renewal and multi-lineage differentiation potential. Conventional two-dimensional (2D) culture systems may hinder therapeutic efficacy due to challenges in maintaining quality and producing a sufficient quantity of cells for clinical applications. This study aimed to evaluate the influence of a three-dimensional (3D) microcarrier-bioreactor system on the biological characteristics of human umbilical cord MSCs (hUC-MSCs) and their potential therapeutic efficacy in a psoriasis mouse model. The 3D microcarrier-bioreactor system was observed to improve hUC-MSCs attachment and proliferation while preserving genetic stability, characteristic surface marker expression, non-tumorigenic properties, and differentiation potential, consistent with outcomes from 2D cultures. Moreover, the 3D-hUC-MSCs demonstrated enhanced proliferation, stemness, immune function, and cell viability compared to those cultured in 2D systems.

Indexed as

Mesenchymal Stem CellsMesenchymal Stem Cell TransplantationPsoriasisUmbilical CordAnimalsBiomimeticsBioreactorsCell Culture Techniques, Three DimensionalCell DifferentiationCell ProliferationCells, CulturedDisease Models, AnimalHumansMiceSignal TransductionhUC-MSCsIL-17/NF-kB signalingmicrocarrier-based 3D culturepsoriasisstemness

Identifiers

PMID41710877
PMCPMC12909563

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.